RESULTS:
Red blood cell and platelet size parameters as well as coagulation activation all were within 3% of baseline values. P-selectin expression on platelets increased by an average of 10.9% relative to baseline. Hemolysis increased with flow through the microfluidic channel, but percentage hemolysis remained below 0.3%.
CONCLUSION:
Blood parameters in a single-pass, microfluidic acoustic cell-separation apparatus remained within normal limits. In vivo animal studies that model continuous separation in a physiologic environment are warranted. P lasmapheresis separates plasma from cellular blood elements by taking advantage of the physical properties of blood. Plasmapheresis by centrifugation uses differences in density, and plasmapheresis by filtration uses differences in particle size to separate plasma from blood cells. In acoustic cell separation, also called acoustophoresis, acoustofluidics, or acoustic apheresis, ultrasonic waves move cells toward specific streamlines as they flow through a microchannel. 1, 2 As the cells form a stream, the cells can then be separated from plasma at branched outlets. Acoustic cell separation relies on physical properties of size, density, and compressibility of particles in suspension. 3 Microscale channels are necessary for this technology to establish stable standing waves in pressure 4, 5 and preserve laminar flow. With an array of microfluidic channels approximately 1 mm in diameter, extracorporeal volumes in an apheresis circuit would be much smaller than current technology yet would achieve sufficient throughput.
Reasons to pursue the development of acoustic apheresis technology are manifold. The small extracorporeal volume of a microfluidic network has clear advantages in neonatal and pediatric therapies. Apheresis has not been thoroughly explored for neonatal diseases in which plasmapheresis may be beneficial, for example, hemolytic disease of the newborn, congenital lupus, and neonatal liver failure. A neonatal-specific device would motivate new areas of pediatric apheresis research, much as a new neonatal dialysis machine has done. 6 In addition, unlike conventional apheresis, an acoustic apheresis circuit will exchange whole blood when acoustics are turned off. This could provide an automated means to perform neonatal whole blood exchange. For patients of all ages, a small device that can operate at low flow rate may potentially be simpler to operate than current technology, thereby reducing capital and training costs for apheresis. With a smaller and simpler device, the constant, direct supervision needed for current apheresis technology may not be necessary, opening the possibility for continuous, low-flow apheresis-a concept that has advantages for patients with cardiovascular instability and for less urgent inpatients who receive no apheresis treatments on nights and weekends. Much as how continuous veno-venous hemodialysis can be performed by a wider array of staff and extend the availability of hemodialysis, acoustic apheresis may expand the utilization of apheresis. These potential uses of acoustic apheresis motivate the development of this technology.
Although bolus, high-flow apheresis would be preferable in many situations where rapid exchange/removal is important (e.g., blood donor collection and emergent apheresis), there may be a niche for acoustic apheresis in expanding apheresis access. Acoustic separation of plasma from cellular blood elements is more straightforward than separation of different cellular elements from each other, so it is likely that plasmapheresis will initially be developed.
As acoustic apheresis technology progresses toward clinical development, establishing the safety of using acoustic energy on blood is paramount. We previously developed disposable, rectangular, polystyrene microchannels for acoustophoresis, measured separation of red blood cells (RBCs) from plasma, and estimated applied acoustic energy density. 7 Subsequently, with further tuning of operating parameters, we attained 94% recovery of RBCs and 91% recovery of leukocytes; and, under different conditions, we attained 92% platelet recovery. 8 Blood was diluted in those studies (input hematocrit [Hct] , approximately 8%-15%), so standard metrics of plasma removal efficiency (PRE) do not apply, but the "plasma" fraction removed comprised at least 40% of the processed volume of dilute solution. Using an etched silicon and glass chip and an Hct of 40%, Lenshof and colleagues described greater than 99% RBC recovery and PRE estimated at 21%. 9 Meanwhile, multichannel microfluidic devices are in development that show how arrays of microchannels can be scaled to clinically relevant flow rates. 10 The engineering of acoustic systems to meet the requirements for PRE, purity, and throughput remains an area of active research.
In this study, we tested blood parameters after processing by an acoustic apheresis microchannel. We hypothesized that the acoustic energy delivered via ultrasound would not cause clinically significant changes in hematologic parameters, because the ultrasound energy used is lower than the energy used by many clinical ultrasound devices that have been established as safe, for example, in echocardiography and obstetrics (range, 2-10 MHz). Here, we applied acoustic frequency and energy relevant for plasmapheresis, causing cells to migrate toward the center of the channel (i.e., acoustic "focusing"), leaving a layer of plasma at the microchannel edges. Studies evaluating new apheresis devices typically include laboratory tests to detect RBC, platelet, and coagulation perturbations. [11] [12] [13] We used those prior studies as a guide to clinically important laboratory tests for evaluating a novel acoustic apheresis microfluidic device.
MATERIALS AND METHODS

Study design
The experiment described below was repeated three times (n 5 3 replicates) in its entirety, each on a different day, using a fresh blood sample from a different donor and a different microchannel; and the final assays were performed independent of the other replicates and on different days. Each replicate used several vacutainers from the same donor pooled into a 20-mL volume. This input sample was pumped continuously by syringe pump as the syringe nozzle was connected, sequentially, to: 1) the device with acoustic power on ("ON" sample); 2) the same device with power off ("OFF" sample); and 3) a length of tubing instead of the device ("NONE" sample). The ON, OFF, and NONE samples were compared by several measures to observe changes caused by the acoustic energy and/or the microchannel. The NONE sample was intended to serve as an experimental control for the condition of the blood after all of the handling steps except for exposure to our device. The OFF sample was intended to control for changes induced by the device (e.g., exposure to materials, flow condition) but not by acoustic energy. The experimental procedure is described in more detail below. The small number of replicates reflects the nature of this study to determine whether more extensive ex vivo safety and performance studies are warranted.
Microchannel fabrication
We fabricated polystyrene microchannel "chips" according to previously described methods. 7 Briefly, a rectangular microchannel (0.43 mm wide, 0.2 mm deep, and 3 cm long) was precision milled into sheets of commercial polystyrene 1 mm thick. To receive inlet and outlet tubing, a recess of larger dimensions was milled at each end of the channel, and matching recesses were cut into the cover plate, which also was 1-mm polystyrene. The outer dimensions of the channel plate and cover plate were 2.54 mm wide and 3.5 cm long. The components were rinsed with isopropyl alcohol and further cleaned in oxygen plasma in a parallel plate reactor immediately before bonding. They were then aligned and bonded to each other under heat and pressure in a custom pneumatic press, using shims and a compressible fiberboard to modulate pressure. Bond temperature was 988C and duration was 50 minutes. Medicalgrade vinyl tubing (Scientific Commodities) with an inside diameter of 0.279 mm and an outside diameter of 0.635 mm was glued into the sockets in the chip with epoxy (MS-907; Miller Stephenson). Quality of the bond and connectors was confirmed by pumping water at 1 mL per minute and visually inspecting for leaks. The combined internal volume of the microchannel and its connecting tubing was approximately 0.01 mL.
Acoustic actuation
We mounted the microchannel chips to conventional (lead zirconate titanate) piezoelectric bulk acoustic actuator plates using cyanoacrylate glue. The actuators were custom fabricated by the vendor (American Piezo Ceramics) to a size slightly wider and shorter than the chip and had a nominal resonant frequency of 1.1 MHz. Actuators were connected by coaxial cable to a radio frequency amplifier driven by a function generator that supplied a sine wave. An oscilloscope monitored the voltage and current delivered to the transducer.
The assembled transducer and microchannel were clamped to a temperature-control stage, which regulates temperature at 308C. The thermistor temperature probe was attached to the surface of the transducer. The stage comprised an aluminum top plate serving as heat sink, an aluminum bottom plate serving as heat exchanger, and a thermoelectric (or Peltier) element sandwiched between them and driven by a temperature controller. The temperature-control stage is needed to dissipate heat generated by the piezoelectric transducer.
Blood samples
Blood drawn from a de-identified, healthy volunteer in sodium citrate vacutainers was purchased from a local supplier (Research Blood Components). The sample was delivered at room temperature by courier within 2 to 3 hours of collection, and experiments began promptly. The maximum duration between collection and completion of post-process plasma collection was 7 hours. Each test sample and its two corresponding controls were processed with blood from a single donor.
Setup and tuning
The experimental acoustic cell separation schema is shown in Fig. 1 . The temperature stage with microchannel was placed under an upright microscope for observation of blood focusing and tuning of actuation parameters. All samples were pumped by syringe pump (PHD2000; Harvard Apparatus) using 20-mL plastic syringes in a horizontal position fitted with 20-gauge tapered polyethylene tips (Nordson). The flow rate was 0.125 mL/min. Syringes were manually rotated periodically throughout the experiments to reduce sedimentation of cells. Outlet samples were collected in open conical centrifuge tubes. Dilute blood was used in setup to determine the optimum acoustic frequency. With the setup sample flowing, the excitation frequency was adjusted in the range from 0.88 to 0.99MHz at moderate power, and the width of the stream of focused cells was observed until a qualitative minimum in width of the stream was determined (i.e., acoustic force on the blood cells was maximized) (Fig. 2) . This frequency was noted and held constant for the duration of the experiment. The setup sample was discarded. 
Acoustophoresis
An undiluted, fresh blood sample, about 20 mL, was loaded into the syringe pump, and flow was started. The transducer was then turned on. Voltage was set to 100 V (approximately 1 W dissipated power to the transducer), focusing of RBCs was visually confirmed, and sample collection of the "ON" sample began until 4 to 6 mL of blood had flowed through the device and was collected in the outlet vial. Without interrupting flow, the transducer power was turned off; then, 4 to 6 mL of blood was collected to obtain the "OFF" sample. Finally, the device was quickly disconnected from the syringe, and a length of tubing (15 cm) identical to that used to connect the microchannel was connected to the syringe. The "NONE" sample was then collected from the outlet of this tubing and pumped at the same rate as the other two samples (0.125 mL/min; also a volume of 4-6 mL). The overall time to collect the three samples was about 2 hours. Our goal was to minimize degradation of the blood due to ageing and handling and to allow all three samples to age equally. Collecting samples sequentially from a single syringe rather than processing three separate syringes had advantages in reducing setup time and overall ageing time, although sedimentation may have been exacerbated.
Sample preparation and analysis
A conventional hematology analyzer (XP-300; Sysmex) was used to aspirate aliquots from the samples for complete blood counts on site. Quest Diagnostics performed tests of plasma free hemoglobin, activated partial thromboplastin time, prothrombin fragment 1.2, and prothrombin time with international normalized ratio. For the tests of coagulation and hemolysis, the blood was centrifuged on-site at 1500 3 g for 15 minutes, and the supernatant plasma was pipetted into individual microcentrifuge tubes for each assay. The prothrombin fragment sample was centrifuged a second time, and the supernatant was transferred to a fresh tube for analysis. The hemolysis test samples were shipped chilled, and the other samples were shipped frozen.
To measure platelet activation, 20 mL of outlet blood samples was pipetted into microcentrifuge tubes with fluorochrome-conjugated antibodies anti-b3 integrin phycoerythrin-cyanin 5(anti-CD61 PE-Cy5), P-selectinplatelet activation-dependent granule membrane protein (CD62p) fluorescein isothiocyanate, or isotype controls; fixed; and shipped chilled for flow cytometry analysis at Children's Hospital Boston, as previously reported. 14 
RESULTS
Blood counts and RBC indices
As shown in Fig. 3 , no significant changes in mean corpuscular volume, mean corpuscular hemoglobin content (MCHC), RBC distribution width, or mean platelet volume measurements were observed among the three samples. Final white blood cell, hemoglobin, Hct, and platelet counts varied from sample to sample. We attribute these changes in cell counts to sedimentation in the syringe over the course of the experiment. Sedimentation of RBCs in the syringe could be clearly discerned by eye. Mean percentage changes were 39% for white blood cells, 25% for hemoglobin, 23% for Hct, and 228% for platelets. Mean percentage change is defined here as the mean of the following quantity, calculated for each replicate: (X ON 2 X NONE )100/X NONE . 
Coagulation factors
Measures of prothrombin time, partial thromboplastin time, and prothrombin fragment 1.2 were within normal levels for each donor sample. No change could be discerned when comparing controls with samples that were processed in the device (Fig. 4) .
Hemolysis
Flowing blood samples through the device resulted in a measurable increase in plasma free hemoglobin; however, this increase was observed with or without acoustic energy applied (Fig. 5) . The control ("NONE") samples had an average level of 7.2 mg/dL, whereas samples exposed to the device had average levels of 25.3 mg/dL. When using the total hemoglobin measure in the controls ("NONE" samples; range, 8.0-12.4 g/dL), there was less than 0.27% hemolysis attributable to the device. The hemolysis sample from one of the three replicates was contaminated by a handling error and could not be measured; hence, results are available from only two replicates.
Platelet activation
Platelet activation as measured by P-selectin showed a mean increase of 10.9% attributable to the device or acoustic energy (Fig. 6) , with the highest measurement at 17.4%. Control samples ranged from 7.12 to 13.86% positive, values which are indicative of low activation in the starting product. attributable to the acoustic device (ON sample) compared with the control sample (NONE). The table reports the mean percentage change from the two or three replicates and also shows the standard deviation of this percentage change.
DISCUSSION
This report summarizes blood health after exposure to a new, disposable acoustic apheresis platform. The fundamental mechanism must be proven safe for blood cells before translation. This study examines the impact of acoustic energy applied to whole blood in polystyrene microchannels with an acoustic energy relevant for plasmapheresis. The measures investigated are complete blood count, hemolysis, coagulation parameters, and platelet activation. Results of these in vitro tests suggest adequate safety to blood cells to pursue additional studies.
We measured hematologic parameters based on measures that were tested in clinical studies of centrifugal apheresis devices.
11-13
Those studies reported no statistically significant changes in coagulation activation when comparing pre-procedure with post-procedure measurements in patient blood. We did identify a decrease in MCHC in one sample and a concomitant increase in free hemoglobin under a condition with flow and acoustics off, followed by a normal MCHC and lower free hemoglobin with flow and acoustics on. We suspect that a pre-analytical or experimental source of error caused this outlying value.
Clinical trials of centrifugal apheresis demonstrate relative changes in vivo of hemoglobin and Hct of approximately 3% from before to after the procedure. 12, 13, 16 Similarly, acoustic energy applied to microfluidic flow resulted in less than 2% changes in RBC parameters compared with control samples. For centrifugal apheresis devices, changes in thrombin generation and platelet activation are more evident than RBC changes. Tormey and coworkers noticed a nearly 50% decrease in prothrombin fragment 1.2 after plasmapheresis, 12 whereas Winters and colleagues noticed an approximately 30% increase in this parameter. 13 Patient selection may contribute to the observed differences. We observed a less than 3% relative change in prothrombin fragment 1.2. CD62p expression on the platelet surface is easily induced with clinically acceptable procedures, such as platelet component washing (47% of platelets express CD62p) 17 and apheresis platelet collection (up to 62% of platelets express CD62p). 18 In our experiments, CD62p expression remained below 20%. Plasma free hemoglobin in clinical testing is generally less than 10 mg/dL at normal Hct levels. 12, 13 Plasma free hemoglobin after RBC transfusion is commonly greater than 100 mg/dL without adverse clinical effect. 19 We hypothesize that our values of free hemoglobin were higher due to the use of ex vivo blood and the absence of in vivo mechanisms that clear free hemoglobin. Indeed, hemolysis in waste plasma after clinical plasmapheresis is usually less than 1 mg/dL, and the starting plasma free hemoglobin in our collected blood was nearly 10 mg/dL. 13 Hemolysis up to 1% is permitted in stored RBCs according to the US Food and Drug Administration, and the hemolysis we observed was within acceptable limits for reinfusion. Animal model testing will be important to establish in vivo hemolysis measurements that are more directly comparable to clinical study data. In addition, we note that elevation in free hemoglobin was observed even with acoustic energy off, suggesting that the microdevice, and not the acoustic energy, contributes to apparent hemolysis. Hydrodynamic conditions, including high shear, can induce hemolysis, and such conditions can be exacerbated in microchannel junctions. 20, 21 The port design in our devices was not optimized and could be responsible for the effect. An improved port design that eliminates abrupt transitions in hydraulic diameter may reduce shear-induced hemolysis. Overall, the in vitro nature of our experiments limits the generalizability of comparisons with clinical results because of our use of collected blood, and not in vivo blood, for experiments; utilization of fluid paths and connections that were not optimized for clinical use; the absence of in vivo, homeostatic mechanisms in our experiments; and an experimental design that does not recapitulate a complete apheresis circuit. It is premature to predict the safety of acoustic apheresis clinically; however, at this stage, there are no safety signals that prohibit continuing the development of this device. Animal models of continuous acoustic apheresis circuits are needed for the next safety assessments.
There are limitations to our study. First, at this early stage in applied acoustic apheresis, we only tested blood ex vivo. Blood may behave differently when it is circulated in vivo after acoustic separation. We controlled for ex vivo effects by comparing results with baseline, unprocessed blood measurements. Second, we only tested blood parameters in the context of flow through the microfluidic channel with or without acoustics on. We did not test a complete system with collect and return pumps, anticoagulant infusion, or plasma removal and replacement. We would anticipate that the effects of the apheresis circuit would be common to all platforms. The goal of this study was to isolate and analyze the effect of acoustic energy applied to blood. Third, we did not test extreme levels of acoustic energy. Higher energy heats the device, and thermal effects would confound the data. However, the energy applied is suitable for plasmapheresis and achieves greater than 90% cell recovery in our comparable acoustic separation devices. Figure 2 shows how the applied energy causes cells to migrate toward the center of the channel using diluted blood. Without dilution, as in the tests performed here, it is difficult to optically assess the purity of the plasma fraction at the edges of the channel. Previously, we demonstrated how downstream branched outlets are used at these energy levels to separate plasma and cell fractions. 7 Fourth, this study provides no conclusive results on changes in cell counts attributable to the device. These results corroborate reports of other acoustic cell manipulation experiments performed in etched silicon or glass research devices. J€ onsson and colleagues reported no increase in hemolysis in acoustic separation of simulated emboli from diluted bovine blood. 22 Adams and coworkers reported a slight increase in platelet activation when acoustically separated from RBCs in highly diluted blood samples, although the activation was not quantified. 23 Dykes and coworkers confirmed greater than 97% viability of peripheral blood progenitor cells and median 20% platelet activation after acoustic separation from diluted leukapheresis product. 24 Burguillos and colleagues used mitochondrial respiratory function to demonstrate the safety of acoustic energy on leukocytes and platelets. 25 The latter study also provides a good summary of further examples demonstrating normal viability or function of various other mammalian cells after acoustic manipulation. 22 Taken together, the current article and the previous studies provide evidence that acoustophoresis can be safely applied to therapeutic extracorporeal blood processing. Further preclinical testing of full-scale systems will be needed as development of the device progresses.
